Comparative Pharmacology
Head-to-head clinical analysis: HYDRA ZIDE versus HYDRAP ES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRA ZIDE versus HYDRAP ES.
HYDRA-ZIDE vs HYDRAP-ES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydra-Zide is a combination of hydrochlorothiazide (thiazide diuretic) and hydralazine (direct vasodilator). Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing electrolyte reabsorption and increasing urine output. Hydralazine relaxes arteriolar smooth muscle, decreasing systemic vascular resistance and afterload.
Hydralazine is a direct-acting vasodilator that relaxes arteriolar smooth muscle, leading to decreased systemic vascular resistance and reduced blood pressure. The exact molecular mechanism involves inhibition of inositol trisphosphate (IP3)-induced calcium release from the sarcoplasmic reticulum and activation of guanylate cyclase, increasing cGMP levels.
Oral, 1 tablet (25 mg hydrochlorothiazide / 50 mg hydralazine) twice daily, titrated up to maximum of 2 tablets twice daily based on blood pressure response.
Oral: 25-50 mg twice daily, max 200 mg/day. IV: 10-20 mg every 4-6 hours as needed.
None Documented
None Documented
Hydralazine: 2-4 hours (fast acetylators), 4-8 hours (slow acetylators); thiazide: 6-15 hours.
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged in renal impairment (up to 20 hours in severe cases).
Renal: 50-70% of hydralazine as metabolites, 30-40% as parent drug; thiazide: 95% renal as unchanged drug.
Primarily renal (80-90% as unchanged drug); minor biliary/fecal (<10%).
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination